Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Australia / NCT07816172
Starting soon Phase 2

Effects of Macanity on Urinary Health in Males With Lower Urinary Tract Symptoms

NCT07816172 · tracked via the Priya Life Science Australia tracker
Sponsor
RDC Clinical Pty Ltd
Phase
Phase 2
Started
2026-09
Last updated
2026-09-11

Condition(s) studied

Lower Urinary Tract Symptoms (LUTS)

Investigational drug(s) / intervention(s)

Maca RootPlacebo

Maca Root: Participants will take 2 capsules daily for 12 weeks, total daily dose of 290mg Macanity.

Placebo: Participants will take 2 capsules of placebo daily for 12 weeks.

Study summary

The goal of this study is to evaluate the effects of Macanity on urinary health in males experiencing LUTS. Males aged over 40 years of age who experience LUTS will be recruited and assigned to a study treatment which they will take for 12 weeks. They will have 3 remote visits over 12 weeks.

Eligibility

Sex
MALE
Min age
40 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Adult males \> 40 years of age experiencing LUTS * Generally healthy * BMI 18-32 kg/m2 * Moderate International Prostate Symptom Score (IPSS) score: 8-19. * IPSS quality of life (QoL) score \>3 * Able to provide informed consent * Agree to not participate in another clinical trial while enrolled in this trial Exclusion Criteria: * Have a serious illness e.g. mood disorders such as depression or bipolar disorder, anxiety, neurological disorders such as MS, kidney disease, liver disease, heart conditions, hypertension * Have an unstable illness e.g. diabetes and thyroid gland dysfunction, uncontrolled hypertension with diastolic blood pressure \> 100 mmHg * Prostate specific antigen (PSA) testing \> 2 years ago * Have used a drug/supplement for benign prostatic hyperplasia (BPH) or other urological symptoms within the last 30 days * Have had a urinary infection in the last 30 days or have, chronic urinary tract infections, or diagnosed chronic prostatitis * Have had urogenital surgery within the last 6 months * Have had bladder biopsy and/or cystoscopy and biopsy within the past 30 days. * Have been diagnosed with chronic persistent local pathology (e.g. interstitial cystitis, bladder stones) * Current malignancy including prostatic cancer (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years * Currently taking Coumadin (Warfarin), Heparin, Dalteparin, Enoxaparin or other anticoagulation therapy including low dose aspirin; antihypertensive medications, tetracyclic antidepressants, thyroid medications * Active smokers, nicotine use or drug (prescription or illegal substances) abuse * Chronic past and/or current alcohol use (\>21 alcoholic drinks per week) * Allergic to any of the ingredients in active or placebo formula, or an allergy to cruciferous vegetables * Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month * Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion

Primary outcome measure(s)

  • Change from baseline to the end of the study period in IPSS — Baseline to 12 weeks
    Change from baseline to the end of the study period in overall IPSS score, IPSS QoL score and individual IPSS items between baseline and each assessment time.

Trial sites (1)

FacilityCityRegionStatus
RDC Clinical Fortitude Valley Queensland

More RDC Clinical Pty Ltd trials in Australia

Supplementation Absorption Comparison Recruiting
Long-Term PEA Safety Study Active, not recruiting
A Study to See if an Energy Drink With Caffeine and Green Tea Increases Fat Burning When Exercising Active, not recruiting
Sleep and Stress Study Recruiting
Gut Microbiome and Metabolic Health Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07816172 on ClinicalTrials.gov ↗ ← All trials in Australia